drugset / Trial / NCT05340231

An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)

NCT05340231

Phase 2 Unknown 100 enrolled Gang Wu
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, open-labelled study to evaluate the efficacy and safety of sequetial transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of initial unresectable colorectal cancer. The progression-free-survival (PFS) will be evaluated as the primary endpoints.

Timeline

Start
2022-05-01
Primary completion
2022-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxaliplatin Small molecule 85 mg/m2 Other
Subject Oxaliplatin Small molecule 85 mg Other
Subject Raltitrexed Small molecule 3 mg Other
Subject lipiodol Unknown 10 ml Other
Background Lidocaine Other / unclassified 1 ml

Indications